Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.
Definition of the optimal pneumococcal vaccine strategy in HIV-infected adults is still under evaluation. We aimed to compare immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) versus the 23-valent polysaccharide vaccine (PPSV23) in HIV-infected adults.We performed a p...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4892598?pdf=render |
| _version_ | 1818457135111995392 |
|---|---|
| author | Francesca Lombardi Simone Belmonti Massimiliano Fabbiani Matteo Morandi Barbara Rossetti Giacinta Tordini Roberto Cauda Andrea De Luca Simona Di Giambenedetto Francesca Montagnani |
| author_facet | Francesca Lombardi Simone Belmonti Massimiliano Fabbiani Matteo Morandi Barbara Rossetti Giacinta Tordini Roberto Cauda Andrea De Luca Simona Di Giambenedetto Francesca Montagnani |
| author_sort | Francesca Lombardi |
| collection | DOAJ |
| description | Definition of the optimal pneumococcal vaccine strategy in HIV-infected adults is still under evaluation. We aimed to compare immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) versus the 23-valent polysaccharide vaccine (PPSV23) in HIV-infected adults.We performed a pilot, prospective controlled study enrolling HIV-infected pneumococcal vaccine-naïve outpatients, aged 18-65 years with CD4 counts ≥200 cells/μL. Eligible subjects were recruited into two parallel groups: group 1 (n = 50) received two doses of PCV13 eight weeks apart, and group 2 (n = 50) received one dose of PPSV23, as part of their standard of care. Anti-pneumococcal capsular polysaccharide immunoglobulin G concentrations were quantified by ELISA at baseline, 8, 24 and 48 weeks. Clinical and viro-immunological follow-up was performed at the same time points. Unvaccinated, age-matched HIV-negative adults (n = 100) were also enrolled as baseline controls.Pre-vaccination specific IgG titers for each pneumococcal antigen did not differ between study groups but they were constantly lower than those from the HIV-negative controls. After immunization, significant increases in IgG titers were observed in both study groups at each time point compared to baseline, but response to serotype 3 was blunted in group 1. Antibody titers for each antigen did not differ between study groups at week 48. Overall, the proportion of subjects achieving seroprotection and seroconversion to all serotypes was comparable between groups. A marked decrease in IgG levels over time was observed with both vaccines. No relevant adverse reactions were reported in either group.In this population with favorable immune profile, no relevant differences were observed in immunogenicity between PCV13 and PPSV23. Both vaccines were safe and well tolerated.ClinicalTrials.gov NCT02123433. |
| first_indexed | 2024-12-14T22:37:45Z |
| format | Article |
| id | doaj.art-20462175b1da4307a05d4ac0f7d516dc |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T22:37:45Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-20462175b1da4307a05d4ac0f7d516dc2022-12-21T22:45:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01116e015652310.1371/journal.pone.0156523Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.Francesca LombardiSimone BelmontiMassimiliano FabbianiMatteo MorandiBarbara RossettiGiacinta TordiniRoberto CaudaAndrea De LucaSimona Di GiambenedettoFrancesca MontagnaniDefinition of the optimal pneumococcal vaccine strategy in HIV-infected adults is still under evaluation. We aimed to compare immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (PCV13) versus the 23-valent polysaccharide vaccine (PPSV23) in HIV-infected adults.We performed a pilot, prospective controlled study enrolling HIV-infected pneumococcal vaccine-naïve outpatients, aged 18-65 years with CD4 counts ≥200 cells/μL. Eligible subjects were recruited into two parallel groups: group 1 (n = 50) received two doses of PCV13 eight weeks apart, and group 2 (n = 50) received one dose of PPSV23, as part of their standard of care. Anti-pneumococcal capsular polysaccharide immunoglobulin G concentrations were quantified by ELISA at baseline, 8, 24 and 48 weeks. Clinical and viro-immunological follow-up was performed at the same time points. Unvaccinated, age-matched HIV-negative adults (n = 100) were also enrolled as baseline controls.Pre-vaccination specific IgG titers for each pneumococcal antigen did not differ between study groups but they were constantly lower than those from the HIV-negative controls. After immunization, significant increases in IgG titers were observed in both study groups at each time point compared to baseline, but response to serotype 3 was blunted in group 1. Antibody titers for each antigen did not differ between study groups at week 48. Overall, the proportion of subjects achieving seroprotection and seroconversion to all serotypes was comparable between groups. A marked decrease in IgG levels over time was observed with both vaccines. No relevant adverse reactions were reported in either group.In this population with favorable immune profile, no relevant differences were observed in immunogenicity between PCV13 and PPSV23. Both vaccines were safe and well tolerated.ClinicalTrials.gov NCT02123433.http://europepmc.org/articles/PMC4892598?pdf=render |
| spellingShingle | Francesca Lombardi Simone Belmonti Massimiliano Fabbiani Matteo Morandi Barbara Rossetti Giacinta Tordini Roberto Cauda Andrea De Luca Simona Di Giambenedetto Francesca Montagnani Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. PLoS ONE |
| title | Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. |
| title_full | Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. |
| title_fullStr | Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. |
| title_full_unstemmed | Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. |
| title_short | Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. |
| title_sort | immunogenicity and safety of the 13 valent pneumococcal conjugate vaccine versus the 23 valent polysaccharide vaccine in unvaccinated hiv infected adults a pilot prospective controlled study |
| url | http://europepmc.org/articles/PMC4892598?pdf=render |
| work_keys_str_mv | AT francescalombardi immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineversusthe23valentpolysaccharidevaccineinunvaccinatedhivinfectedadultsapilotprospectivecontrolledstudy AT simonebelmonti immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineversusthe23valentpolysaccharidevaccineinunvaccinatedhivinfectedadultsapilotprospectivecontrolledstudy AT massimilianofabbiani immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineversusthe23valentpolysaccharidevaccineinunvaccinatedhivinfectedadultsapilotprospectivecontrolledstudy AT matteomorandi immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineversusthe23valentpolysaccharidevaccineinunvaccinatedhivinfectedadultsapilotprospectivecontrolledstudy AT barbararossetti immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineversusthe23valentpolysaccharidevaccineinunvaccinatedhivinfectedadultsapilotprospectivecontrolledstudy AT giacintatordini immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineversusthe23valentpolysaccharidevaccineinunvaccinatedhivinfectedadultsapilotprospectivecontrolledstudy AT robertocauda immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineversusthe23valentpolysaccharidevaccineinunvaccinatedhivinfectedadultsapilotprospectivecontrolledstudy AT andreadeluca immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineversusthe23valentpolysaccharidevaccineinunvaccinatedhivinfectedadultsapilotprospectivecontrolledstudy AT simonadigiambenedetto immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineversusthe23valentpolysaccharidevaccineinunvaccinatedhivinfectedadultsapilotprospectivecontrolledstudy AT francescamontagnani immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineversusthe23valentpolysaccharidevaccineinunvaccinatedhivinfectedadultsapilotprospectivecontrolledstudy |